PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Pfizer recalls migraine med Relpax because of bacterial contamination

Migraine headache/epilepsy brain image

For the second time in four months, Pfizer is voluntarily recalling some lots of its Relpax migraine drug. (creative commons)

After an earlier recall of Relpax, Pfizer is again tracking down a couple of lots of the migraine headache med. This time, however, instead of a labeling issue, it is because the affected drugs may be contaminated with bacteria that could cause fatal infections in some patients.

Pfizer Wednesday issued the nationwide voluntary recall for the 40 mg tablets, saying they may be tainted by the bacteria genera pseudomonas and burkholderia. So far, Pfizer has received no reports of adverse events but said for patients with some diseases, such as cystic fibrosis, a bacterial infection can be very serious, even fatal. 

The two lots of Relpax (eletriptan) were distributed throughout the U.S. and Puerto Rico in June and July. 

In late April, Pfizer had recalled five lots of Relpax. In that case, it was because there was an artwork error on the secondary packaging indicating the meds were 20 mg tablets instead of 40 mg tablets.  

Relpax, which has been off patent in the U.S. since 2016, is not a big seller, bringing in only $90 million last year. The older migraine drugs have been eclipsed by a new generation of injected migraine treatments which offer longer-lasting relief but come with big price tags. 

Amgen’s Aimovig, Teva’s Ajovy and Eli Lilly’s Emgality carry list prices of $6,900 per year but can be injected monthly, or in some cases quarterly, to offer extended relief.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026